Integrating predictive biomarkers and classifiers into oncology clinical development programmes

2011 ◽  
Vol 10 (10) ◽  
pp. 735-748 ◽  
Author(s):  
Robert A. Beckman ◽  
Jason Clark ◽  
Cong Chen
Keyword(s):  
Predictive Biomarkers ◽  
Clinical Development

scholarly journals Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors

2009 ◽  
Vol 2009 ◽  
pp. 1-12 ◽  
Author(s):  
Ann Marie Egloff ◽  
Jennifer Rubin Grandis
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Targeted Therapies ◽  
Kinase Inhibitors ◽  
Growth Factor Receptor ◽  
Predictive Biomarkers ◽  
Clinical Development ◽  
Targeted Therapeutics

The epidermal growth factor receptor- (EGFR-) directed antibody, cetuximab, was FDA-approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in 2006. Additional EGFR-targeting agents in clinical development for SCCHN include other EGFR-directed antibodies, tyrosine kinase inhibitors and antisense DNA. Although the majority of SCCHN overexpress EGFR, SCCHN clinical responses to EGFR-targeting agents have been modest. Molecular predictors for SCCHN response to EGFR-targeted therapies have not been identified. However, molecular correlate studies in lung cancer and colon cancer, which have EGFR-targeted therapeutics FDA-approved for treatment, may provide insights. We describe candidate predictive markers for SCCHN response to EGFR-targeted therapies and their prevalence in SCCHN. Clinical response will likely be improved by targeted therapy combination treatments. Src family kinases mediate EGFR-dependent and -independent tumor progression pathways in many cancers including SCCHN. Several Src-targeting agents are in clinical development for solid malignancies. Molecular correlate studies for Src-targeting therapies are few and biomarkers correlated with patient response are limited. Identifying SCCHN patients who will respond to combined EGFR- and Src-targeting will require further characterization of molecular correlates. We discuss rationale for EGFR and Src co-targeting for SCCHN treatment and describe recent clinical trials implementing combined Src- and EGFR-targeted therapeutics.

scholarly journals Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine

2021 ◽  
Vol Volume 14 ◽  
pp. 1517-1535
Author(s):  
Niamh Coleman ◽  
Justin T Moyers ◽  
Alice Harbery ◽  
Igor Vivanco ◽  
Timothy A Yap
Keyword(s):  
Predictive Biomarkers ◽  
Clinical Development ◽  
Patient Treatment ◽  
Cancer Medicine

COVID-19 must catalyse changes to clinical development

2020 ◽  
Vol 19 (10) ◽  
pp. 653-654
Author(s):  
Rod MacKenzie ◽  
Peter Honig ◽  
Judy Sewards ◽  
Robert Goodwin ◽  
Marie-Pierre Hellio
Keyword(s):  
Clinical Development

Curcumin: New trends in the formulative and clinical development

Planta Medica ◽  
2014 ◽  
Vol 80 (10) ◽  
Author(s):  
P Morazzoni ◽  
A Riva ◽  
M Ronchi ◽  
G Petrangolini ◽  
W Cabri
Keyword(s):  
Clinical Development
Sign in / Sign up

Export Citation Format

Share Document